Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Characterization of A Novel CRAC Inhibitor that Potently Blocks Human T cell Activation and Effector Functions


ABSTRACT: Store operated calcium entry (SOCE) downstream of T cell receptor (TCR) activation in T lymphocytes has been shown to be mediated mainly through the Calcium Release Activated Calcium (CRAC) channel. Here, we compared the effects of a novel, potent and selective CRAC inhibitor, 2,6-Difluoro-N-{5-[4-methyl-1-(5-methyl-thiazol-2-yl)-1,2,5,6-tetrahydro-pyridin-3-yl]-pyrazin-2-yl}-benzamide (RO2959), on T cell effector functions with that of a previously reported CRAC channel inhibitor, YM-58483, and a calcineurin inhibitor Cyclosporin A (CsA). Using both electrophysiological and calcium-based fluorescence measurements, we showed that RO2959 is a potent SOCE inhibitor that blocked an IP3-dependent current in CRAC-expressing RBL-2H3 cells and CHO cells stably expressing human Orai1 and Stim1, as well as SOCE in human primary CD4+ T cells triggered by either TCR stimulation or thapsigargin treatment. Furthermore, we demonstrated that RO2959 completely inhibited cytokine production as well as T cell proliferation mediated by TCR stimulation or MLR (Mixed Lymphocyte Reaction). Lastly, we showed by gene expression array analysis that RO2959 potently blocked TCR triggered gene expression and T cell functional pathways similar to CsA and FK506. Thus, both from a functional and transcriptional level, our data provide evidence that RO2959 is a novel and selective CRAC inhibitor that potently inhibits human T cell functions. PBMC from healthy donors (n=4) were stimulated with anti-CD3/CD28 in the presence or absence of CRAC inhibitor, CsA or FK506 for 24 hrs

ORGANISM(S): Homo sapiens

SUBMITTER: Kai Lau 

PROVIDER: E-GEOD-43210 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


Store operated calcium entry (SOCE) downstream of T cell receptor (TCR) activation in T lymphocytes has been shown to be mediated mainly through the Calcium Release Activated Calcium (CRAC) channel. Here, we compared the effects of a novel, potent and selective CRAC current inhibitor, 2,6-Difluoro-N-{5-[4-methyl-1-(5-methyl-thiazol-2-yl)-1,2,5,6-tetrahydro-pyridin-3-yl]-pyrazin-2-yl}-benzamide (RO2959), on T cell effector functions with that of a previously reported CRAC channel inhibitor, YM-58  ...[more]

Similar Datasets

2013-01-31 | GSE43210 | GEO
2015-10-24 | E-GEOD-41825 | biostudies-arrayexpress
2012-01-23 | E-GEOD-28492 | biostudies-arrayexpress
2015-10-23 | E-GEOD-41863 | biostudies-arrayexpress
2015-10-23 | E-GEOD-41862 | biostudies-arrayexpress
2015-10-23 | E-GEOD-41861 | biostudies-arrayexpress
2013-10-22 | E-GEOD-41329 | biostudies-arrayexpress
2012-01-31 | E-GEOD-28491 | biostudies-arrayexpress
2012-01-31 | E-GEOD-28490 | biostudies-arrayexpress
2014-04-01 | E-GEOD-54217 | biostudies-arrayexpress